Welcome to our dedicated page for Statera Biopharma news (Ticker: STAB), a resource for investors and traders seeking the latest updates and insights on Statera Biopharma stock.
Introduction
Statera Biopharma Inc (symbol: STAB) is a biopharmaceutical company focused on restoring immune health through a unique approach that leverages complex and pleiotropic beneficial effects. Employing advanced techniques in drug repurposing, the company emphasizes the use of beneficial and safe drugs that mimic natural analogs to trigger paracrine signaling and trans-activation, effectively addressing disease pathways and promoting homeostasis. Keywords such as "immune modulation," "biopharmaceutical innovation," and "drug repurposing" are central to its operational narrative.
Business Model and Core Value Proposition
The company derives its strength from a detailed understanding of the human immune system and the therapeutic potential of safe pharmacological agents. Statera Biopharma develops its proprietary approach by identifying natural compounds that can be repurposed to serve as effective treatments, thereby reducing the risk associated with novel drug development. This model enables a focus on enhancing the body’s natural healing pathways, positioning the firm as a noteworthy player in the field of immune health restoration.
Scientific Rationale and Mechanisms
At the heart of Statera Biopharma’s methodology is the concept of using drugs that act as natural analogs. Such drugs are considered to exhibit pleiotropic effects—influencing multiple biological pathways—which are harnessed in a paracrine fashion. Additionally, these agents serve as trans-activators, facilitating the resolution of disease conditions. By restoring equilibrium within the body, the company aims to reestablish homeostasis and improve health outcomes, a process that is both scientifically intricate and clinically significant.
Market Position and Industry Context
Operating within the larger biotechnology and pharmaceutical sectors, Statera Biopharma navigates a complex market influenced by rigorous scientific standards and evolving regulatory landscapes. The company’s emphasis on therapies that mimic natural biological processes distinguishes it from competitors who primarily rely on completely synthetic or novel chemical approaches. This differentiation places the company within a niche that bridges conventional drug therapy and more innovative, mechanism-based treatments, thereby appealing to stakeholders interested in safe and efficacious therapeutic alternatives.
Operational Insights and Competitive Landscape
Statera Biopharma is mindful of the inherent challenges in translating scientific innovation into clinically effective therapies. Its approach necessitates a robust framework of clinical validation and consistent adherence to safety protocols, ensuring that its strategies remain anchored in scientific rigor and therapeutic promise. While the competitive landscape in the biopharmaceutical sector is formidable, the company’s focus on leveraging naturally occurring analogs and restoring immune balance provides a distinct and defendable market position. In addition, its commitment to exploring the pleiotropic impacts of selected drugs positions it to address a range of immune-mediated conditions.
Research and Development Focus
The company’s research and development efforts are aligned with a strategy that emphasizes the integration of clinical insights with advanced biotechnological methods. By focusing on the underlying mechanisms of immune health, Statera Biopharma advances its pipeline through stages that reflect both scientific inquiry and practical application. This balanced approach allows the company to produce content and data that are not only technically sound but also aligned with broader industry standards, ensuring that its methodologies are both reproducible and scalable.
Conclusion
In summary, Statera Biopharma Inc exemplifies a forward-thinking approach within the biopharmaceutical industry by focusing on the restoration of immune health through natural analogs and complex biological signaling. The company’s expertise in leveraging beneficial drugs to enact homeostasis, combined with its careful navigation of regulatory and market challenges, marks it as a pragmatic and innovative contender in the field of immune modulation. Its operational focus on scientifically validated processes and a transparent, methodical business model provides a rich context for investors and industry analysts seeking a deeper understanding of its market role.
Tivic Health Systems (NASDAQ: TIVC) has acquired worldwide exclusive license rights from Statera Biopharma for Entolimod™, a late-stage TLR5 agonist targeting acute radiation syndrome (ARS). The agreement includes an exclusive option for five additional indications for Entolimod and its derivative, Entalasta™.
This strategic move transforms Tivic from a single-product, direct-to-consumer company into a diversified therapeutics company. Entolimod has received FDA Fast Track and Orphan Drug designation for ARS treatment and has undergone over forty animal and human trials with $140 million in prior investment.
The global ARS market is valued at $5.2 billion in 2024, with a projected 5% annual growth rate through 2031. The acquisition positions Tivic to address immune and autonomic dysregulation through both neural and molecular pathways, with potential FDA approval within 24 months.
Statera Biopharma (OTCPK:STAB) has signed a non-binding letter of intent with Worksite Labs, Inc. to explore a merger. This strategic move aims to enhance shareholder value and operational performance by aligning Statera's goals with Worksite Labs' diagnostic services. Worksite Labs generated over $50 million in revenues in 2022 and aims to leverage capital markets for accelerated growth. Completion of the merger is contingent upon due diligence, definitive agreements, and necessary approvals. Both companies are optimistic about the benefits this combination could bring to their operations and market positioning.
Statera Biopharma (NASDAQ:STAB) has completed its application to uplist from OTC Pink Sheets to the OTCQB Venture Marketplace. This marks a crucial step in its efforts to regain a NASDAQ listing. The company anticipates that this transition will lead to improved investor benefits, including enhanced reporting standards and increased visibility among analysts and institutional investors. The addition of CG Capital as an advisor aims to further increase trading liquidity and broaden STAB's shareholder base. Statera develops immune therapies targeting autoimmune diseases, cancers, and emerging viruses based on a proprietary platform.
Statera Biopharma, a biopharmaceutical company (NASDAQ:STAB), received a favorable decision from the Nasdaq Hearings Panel, allowing them to maintain their listing on Nasdaq, contingent upon meeting specific interim milestones. This decision was made on October 26, 2022, requiring compliance with the $1.00 bid price and $2.5 million stockholders' equity standards by January 31, 2023. The company specializes in developing innovative immune therapies targeting autoimmune diseases and cancers, positioned to enhance patient immune responses using toll-like receptor (TLR) agonists.
Statera Biopharma (NASDAQ:STAB) filed its Q1 Form 10-Q for the period ending March 31, 2022, with the SEC, while also working on the Q2 report. The company secured an agreement with Silverback Capital to acquire $400,000 of a $15 million promissory note, converting it into an amended convertible note due May 1, 2024. This move aims to enhance Statera's financial standing. CEO Michael Handley expressed confidence in complying with NASDAQ regulations and hopes for further note conversions to improve the balance sheet.
Statera Biopharma (NASDAQ:STAB) has signed a MOU with Holobeam Technologies to acquire a 25% stake, granting access to Holobeam's innovative diagnostic technology. This partnership aims to enhance early cancer detection and treatment efficacy through Holobeam's patented Holographic Energy Teleportation (HET) technology, which promises to identify cancers earlier and target therapies more precisely. The exclusivity period for finalizing the agreement is set for 60 days. The alliance could significantly improve the therapeutic outcomes for cancer patients by enabling targeted drug delivery and early intervention.
Statera Biopharma (NASDAQ:STAB) announced the completion of its fiscal 2021 audit and filed its Annual Report on Form 10-K with the SEC. The company is now focused on filing Forms 10-Q for the first three quarters of 2022. At a Nasdaq hearing, Statera presented its compliance plan and requested an extension for continued listing. However, there is no assurance the request will be granted. Statera develops innovative immunotherapies targeting autoimmune diseases and cancers, leveraging a robust platform of TLR agonists.
Statera Biopharma (NASDAQ:STAB) announced on September 1, 2022, that it may face delisting from Nasdaq due to non-compliance with filing requirements. The company has not filed its Form 10-K for 2021 or the Forms 10-Q for the first two quarters of 2022. A hearing has been requested, scheduled for October 6, 2022, to seek an extension and demonstrate compliance. Statera develops immunotherapies for autoimmune diseases and cancers, with several clinical programs underway.
Statera Biopharma (NASDAQ: STAB) announced it received another notice of non-compliance from Nasdaq due to its failure to timely file the Form 10-Q for Q2 2022 with the SEC. This follows previous notices regarding the company's Forms 10-K and 10-Q for earlier periods. Statera intends to submit a plan to regain compliance within the allotted timeframe, which allows for a maximum of 180 days from the initial delinquent filing due date of October 17, 2022. However, the company cannot assure that it will meet Nasdaq’s compliance criteria.
Statera Biopharma (NASDAQ: STAB) has appointed BF Borgers CPA PC as its independent accountant to audit its financial statements for the year ended December 31, 2021. This move aims to enhance transparency and reliability in Statera’s financial reporting. The company specializes in developing immune therapies to address autoimmune diseases, cancers, and emerging viruses, leveraging its proprietary platform. Statera's clinical programs include treatments for Crohn’s disease, hematology, pancreatic cancer, and COVID-19.
FAQ
What is the current stock price of Statera Biopharma (STAB)?
What is the market cap of Statera Biopharma (STAB)?
What is the core focus of Statera Biopharma Inc?
How does the company approach drug development?
What differentiates Statera Biopharma from other biotech companies?
What industry does Statera Biopharma operate in?
What is the significance of pleiotropic effects in their approach?
How does the company ensure the safety of its therapeutic agents?
What challenges does the company face in the market?
How does Statera Biopharma contribute to the field of immune modulation?
